Signal Transduction and Targeted Therapy

Article	Citations
Cocktails of defined chemical compounds: sufficient to induce totipotency in embryonic stem cells	2021
Somatic mutant clone screening: scan for novel NASH target genes in mouse liver	1876
Dopamine as a teaching signal: understanding its role in shaping individual behavior	1672
Interaction between CDC6 and Tmod3 accelerates resistance to paclitaxel through focal adhesion assembly	1540
A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease	1481
Boosting liver regeneration: kinase inhibitor as a new tool to prevent liver failure	1428
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster	1409
Correction: Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis	1351
Moving towards precision psychiatry: the hard nut of depression	1309
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5	1239
Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis	1221
Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection	1179
Comparing acute versus AIDS ART initiation on HIV-1 integration sites and clonal expansion	1170
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates	1104
Massively parallel interrogation of human functional variants modulating cancer immunosurveillance	1080
Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells	1076
Inducible CD147 up-regulation boosts extended SARS-CoV-2 infection triggering severe COVID-19 independent of ACE2	1055
csRNA and heparan sulfate : cell surface ribonucleoproteins regulate HS-mediated signaling	1036
Correction: The Hippo signalling pathway and its implications in human health and diseases	1028
Chemo-photothermal synergy ignites antitumor immunity via ferroptosis	1020
A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer	952
Sensory neurons: unveiling the symphony of wound healing	940
Identification of glutamine as a potential therapeutic target in dry eye disease	930
Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis	930
Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics	923

Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness	912
Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE	906
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies	895
CD4 T cell contact drives macrophage cell cycle G0-G1 transition	892
Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma	858
PD-1 and LAG-3: synergistic fostering of T cell exhaustion	858
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration	849
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study	846
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages	814
Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms	809
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study	808
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects	788
Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets	787
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases	776
Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications	774
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders	773
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study	711
Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis	695
Phototherapy in cancer treatment: strategies and challenges	664
Neutrophil extracellular traps in homeostasis and disease	662
Omicron spike protein: a clue for viral entry and immune evasion	652
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology	648
Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters	647
Top(ological-operon) secret behind the long-range transcriptional coupling	640
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN	633
Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer	628
Age-induced changes in lung microenvironment: from melanoma dormancy to outgrowth	616
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies	606
The Gdf15-xenobiotic receptor axis shapes NK cell maladaptation predicting cold tumors under environmental stress	598
Necroptosis triggers inflammatory interferon signatures in patient-derived metastatic breast cancer organoids	595
Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia	589
“Good” fats, bad news: HDL-delivered vitamin E shields tumors from ferroptosis	581
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)	569
Novel post-transcriptional dimension of glucocorticoid action through mRNA translation and P-body remodeling	564
Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression	557
Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy	549
From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism	548
The RING finger protein family in health and disease	526
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma	510
Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy	507
Neurotransmitter modulation: a roadmap to precision neuro-immune oncology	502
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy	502
Docking protein 6 (DOK6) selectively docks the neurotrophic signaling transduction to restrain peripheral neuropathy	499
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors	480
Drugging the intrinsically disordered transactivation domain of androgen receptor	462
Beyond borders: the choroid plexus-immune communication during neuroinflammation	459
Lysophosphatidylethanolamine 18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism	458
Microglia-derived nanovesicles synchronize macroautophagy and chaperone-mediated autophagy for Alzheimer’s disease therapy	455
Ninjurin-1 mediates cell lysis and detrimental inflammation of PANoptosis during influenza A virus infection	445
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	444

Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss	444
Harnessing innate immune pathways for therapeutic advancement in cancer	440
Platelets and diseases: signal transduction and advances in targeted therapy	439
Mind-body control: a new perspective on motor neuron function	438
Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes	436
Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations	433
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus	427
Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia	427
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection	420
Metaplastic epithelial cells: origination from stem cells and promotion of intestinal inflammation	415
Nascent mRNA damage: depot and disposal	413
Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity	409
Spi-1 proto-oncogene regulates mRNA hypertranscription and malignant progression in head and neck cancer	401
Arterial inflammation after myocardial infarction: regulating the immune system	400
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine	398
Landscape of antitumor CD4+ T cells in melanoma:unraveling novel HLA class II-driven immune escape	387
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants	381
PD-1/LAG-3 signaling rewires T-cells via MYC inhibition	379
The cost of cure: cancer therapies sculpt somatic evolution and signaling landscapes in normal tissues	376
Predicting the next move: tracking the complexity of lung cancer evolution and metastasis	375
Targeting fused in sarcoma (FUS): a novel antisense strategy for treating idiopathic pulmonary fibrosis	372
Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases	371
Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer	364
High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming	360
Base editing: a promising tool to rescue spinal muscular atrophy	358
A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury	357
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer	353
DNA framework signal amplification platform-based high-throughput systemic immune monitoring	352
The consensus molecular subtypes of esophageal squamous cell carcinoma	351
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors	345
Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy	343
Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates	334
Mitochondrial heterogeneity in diseases	330
Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression	327
Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis	324
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance	323
GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia	321
Ring finger protein 213 regulates B-cell receptor signaling, metabolism, and development in B lymphocytes	318
Small molecules in the treatment of COVID-19	316
Molecular insights of exercise therapy in disease prevention and treatment	303
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread	302
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors	293
ENO2 drives tumor cell-induced M2 macrophage polarization to promote colorectal cancer liver metastasis	292
RUNX1 promotes mitophagy and alleviates pulmonary inflammation during acute lung injury	291
Lactate metabolism in human health and disease	290
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	290
STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation	283
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	283
CNTNAP2 intracellular domain (CICD) generated by γ-secretase cleavage improves autism-related behaviors	281
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization	277
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases	275
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy	273
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies	266
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	264
Single-cell genomics: the human biomolecular and cell atlases	256
Linking B cell metabolism to immune regulation: the neurotransmitter GABA	256
A new treatment for sarcoma extracted from combination of miRNA deregulation and gene association rules	253
Post-fast refeeding: rise of intestinal stemness and mutagen-induced cancer risk through polyamine metabolism	252
Liquid biomarkers associate with TGF-β Type I receptor and hypoxia in kidney cancer	249
Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1	248
RNA interfering machinery: new insight into the Dicer-2 complexes in the dsRNA-processing cycle	248
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function	248
Targeting TM4SF1 exhibits therapeutic potential via inhibition of cancer stem cells	247
Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control	245
The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2	243
Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer	240
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus	238
Personalized pharmacokinetic–pharmacodynamic guided therapy via an induced pluripotent stem cell–derived multi-organoid platform in NF1-mutant breast cancer	236
Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function	235
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer	233
RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation	233
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration	232
Programmable synthetic receptors: the next-generation of cell and gene therapies	232
C/EBPβ activation in vascular smooth muscle cells promotes hyperlipidemia-induced phenotypic transition and arterial stiffness	232
Pulsed electromagnetic fields inhibit atherosclerosis by regulating pyroptosis through membrane tension-mediated mechanosensitive channels	231
CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia	230
Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection	228
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics	228
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy	226
Stem loop binding protein promotes SARS-CoV-2 replication via -1 programmed ribosomal frameshifting	223

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial	223
SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication	222
Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma	221
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation	218
Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson’s disease: a randomized phase 2 trial	218
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors	216
Current landscape of innovative drug development and regulatory support in China	215
Immunopeptidome profiling in pulmonary fibrosis: linking antigenicity to cytotoxic immunity and therapeutic targeting	215
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling	215
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	213
Glioblastoma at the crossroads: current understanding and future therapeutic horizons	213
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance	213
Signaling pathways and targeted therapies for psoriasis	213
I prostanoid receptor activation attenuates pressure overload-induced cardiac hypertrophy by enhancing glucose oxidation	211
Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation	209
Fever as thermal barrier: avian‑origin PB1 enables influenza A viruses to overcome mammalian febrile defense	206
Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition	205
Reframing cancer cachexia: the vagal brain–liver axis as a novel neuro-metabolic target	201
Universal scaling law: transcription factors homeostatically control promoter activity	200
Environment impacts sexual preference: dopamine sends signals under pressure to decide which sex you like	196
Balancing memory in sleep: firing barrages as a circuit breaker for reactivation	192
Time’s up: mutation rate and lifespan	191
Bat organoid platform: revolutionizing zoonotic virus research and pandemic preparedness	191
Adhesion G protein-coupled receptor latrophilin 1 (ADGRL1): a novel regulator of glucose and energy homeostasis	190
Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance	190
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity	190
Bone morphogenetic protein signaling drives rete ridge morphogenesis: a distinct epidermal appendage program	190
Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells	188
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes	187
Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity	187
BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis	186
Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury	184
Modularization of adhesion G protein-coupled receptor (aGPCR) structure: how alternative splicing regulates synaptogenesis	181
Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming	181
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts	178
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines	173
Activated STING: an ion channel to trigger non-interferon-related functions	173
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study	172
Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells	172
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs	170
Switching tumor-derived extracellular vesicles off and on via targeted proteolysis to shift toward immunogenic phenotypes	169
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial	169
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis	169
Signaling pathways in obesity: mechanisms and therapeutic interventions	168
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial	167
The role of ER-associated degradation and ER-phagy in health and disease	167
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study	166
Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein	165
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation	165
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism	164
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial	162
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies	162
ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression	162
Sound effects: paradigm gene therapy approach installs hearing in children and adolescents born deaf	160
Redox regulation: mechanisms, biology and therapeutic targets in diseases	158
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis	157
Arterial stiffness and vascular aging: mechanisms, prevention, and therapy	156
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential	152
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications	150
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	149
Targeted protein degradation: advances in drug discovery and clinical practice	148
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	147
Human cross-tissue cell atlases: unprecedented resources towards systematic understanding of physiology and diseases	146
Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome	146
A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver	145
SLC7A11: a new regulator in diabetic wound healing	144
Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth	144
Correction: CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism	144
Uveal melanoma with a GNA11/GNAQ mutation secretes VEGF for systemic spread	142
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a	141
tRF-Gln-CTG-026 ameliorates liver injury by alleviating global protein synthesis	140
Artificial intelligence propels lung cancer screening: innovations and the challenges of explainability and reproducibility	140
An oncostatin M receptor and chloride intracellular channel 1 crosstalk drives key oncogenic pathways in glioblastoma	139
DRC3 is an assembly adapter of the nexin-dynein regulatory complex functional components during spermatogenesis in humans and mice	138
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial	138
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes	137
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial	137
Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism	132
PARP1-DNA co-condensation: the driver of broken DNA repair	132
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)	131
Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder	128
Tumor heterogeneity: development, mechanisms, and therapeutic implications	128
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study	128
Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes	125
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomiz	125
FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection	124
Gut dysbiosis conveys psychological stress to activate LRP5/β-catenin pathway promoting cancer stemness	123
CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection	123
GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer	121
IL-17 signaling in skin repair: safeguarding metabolic adaptation of wound epithelial cells	121
DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation	121
The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation	120
Mutation-independent gene knock-in therapy targeting 5′UTR for autosomal dominant retinitis pigmentosa	120
A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol	119
SCGN deficiency is a risk factor for autism spectrum disorder	118